Datamonitor Healthcare Releases Mental Health Statistics
World Mental Health Day 10th October 2013
Independent analysis from Daniel Chancellor, lead analyst at Datamonitor Healthcare.
Major Depressive Disorder (MDD) is by far the most prominent mental health disorder across the US, Japan and the 5 major EU markets (UK, France, Germany, Italy and Spain) with over 32.5 million sufferers.
The market for treating depression is alsolarger than for all other psychiatric disorders and Datamonitor Healthcare estimates that sales of drugs for depression totaled $5.6bn in 2012.
The depression market is well-established and has benefitted from years of investment in R&D and marketing by the leadingpharmaceutical companies. However, the barriers to market entry for new drugs are higher than ever, leading to a considerable scaling back of the involvement of Big Pharma companies such as GlaxoSmithKline, Sanofi, and Pfizer.
Lundbeck is a company which remains committed to psychiatry and was rewarded for itsefforts in September 2013 when it received regulatory approval in the US for its newest antidepressant, Brintellix (vortioxetine).
Brintellix, which is related to the successful SSRI class of antidepressants (includingProzac, Zoloft and Lexapro), has a superior tolerability profile and has shown good efficacy - making it a competitive new treatment option. Datamonitor Healthcare forecasts Brintellix to achieve sales of approximately $900m in the US, Japan and major EU markets for depression in 2021 alone.
Daniel Chancellor is available for interview. To arrange, or for any further information, please contact Joe Dixon or Lucy Giles on +44 161 236 1352 or firstname.lastname@example.org
Notes to editors
About Datamonitor Healthcare: Datamonitor Healthcare provides expert independent analysis of key diseases, drugs and companies, in addition to epidemiological research and strategic insights.
Our experienced specialists use robust data sources and methodologies to produce reliable forecasts and event-sensitiveanalysis in response to changing pharmaceutical market developments. With teams located across developed and emerging countries, we are uniquely placed to understand local healthcare trends and provide accurate and reliable recommendations.
Whenever citing an analyst or quote, please remember to use ‘Datamonitor Healthcare’ rather than ‘Datamonitor’.
For descriptive purposes, Datamonitor Healthcare is a “leading research and consulting firm.”
Whenever possible, please hyperlink:
· The Datamonitor Healthcare name to http://www.datamonitorhealthcare.com
· Any reports used to the correct URL for that listing on our Report Store.
Please note that all supplied to the media, is owned exclusively by Datamonitor Healthcare, is governed by our terms and conditions, and therefore must be referenced.
To find out more about Datamonitor Healthcare please visit:
Posted: October 2013